Sanosurfer has not owned MHAN shares for a long, long time, maybe as long as a year? But he was long and a fan way before I arrived 2 years ago. He has been bearish on the stock for a good year or so if you read his posts, so chill out.
I bought at .02 for months here, when no else else was around. Also bought shares up to .10 nearly a year ago, and held them down to .013, and averaged down. Sold some at .07 today, and bought back at the close at .033
I may buy more tomorrow if goes any lower.
To me the real value is in the 3 new products they have in the pipeline. The other value increase I see is due to the removal of the previously threatened share increase to over 300,000,000 million shares.
.08 a share is going to be hard resistance to break. I expect it trade between .025 or .03 and .06 now, tell more news comes out. I also felt like it should be trading at .20/share a year ago, but Nordic Biotech fund started their put and warrant BS (read the old PRs and SEC reports if you want the entire story and picture, and / or read all the old posts between Sanosurfer and myself the last 12 months..
I bought at .02 for months here, when no else else was around. Also bought shares up to .10 nearly a year ago, and held them down to .013, and averaged down. Sold some at .07 today, and bought back at the close at .033
I may buy more tomorrow if goes any lower.
To me the real value is in the 3 new products they have in the pipeline. The other value increase I see is due to the removal of the previously threatened share increase to over 300,000,000 million shares.
.08 a share is going to be hard resistance to break. I expect it trade between .025 or .03 and .06 now, tell more news comes out. I also felt like it should be trading at .20/share a year ago, but Nordic Biotech fund started their put and warrant BS (read the old PRs and SEC reports if you want the entire story and picture, and / or read all the old posts between Sanosurfer and myself the last 12 months..
Ambition with out knowledge is like ship in dry dock. Going nowhere fast!
Recent TGTX News
- TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI • GlobeNewswire Inc. • 04/15/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/20/2026 08:33:42 PM
- TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million • GlobeNewswire Inc. • 03/19/2026 11:30:00 AM
- Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis • GlobeNewswire Inc. • 03/09/2026 11:30:00 AM
- TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting • GlobeNewswire Inc. • 03/06/2026 12:30:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/27/2026 10:05:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 12:08:34 PM
- TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance • GlobeNewswire Inc. • 02/26/2026 12:00:00 PM
- TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Long Term Data Published in JAMA Neurology Demonstrate Sustained Efficacy and Consistent Safety of BRIUMVI in Relapsing Multiple Sclerosis • GlobeNewswire Inc. • 02/17/2026 12:30:00 PM
- TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis • GlobeNewswire Inc. • 02/08/2026 09:17:55 PM
- TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum • GlobeNewswire Inc. • 02/06/2026 12:30:00 PM
- TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum • GlobeNewswire Inc. • 01/27/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/13/2026 09:27:48 PM
- TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones • GlobeNewswire Inc. • 01/13/2026 09:25:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:16:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:15:33 PM
- TG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/07/2026 12:30:00 PM
- TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference • GlobeNewswire Inc. • 11/28/2025 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/25/2025 10:31:57 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/24/2025 09:04:15 PM
- TG Therapeutics Makes 2025 Deloitte Technology Fast 500™ List of America’s Fastest-Growing Companies • GlobeNewswire Inc. • 11/19/2025 01:30:00 PM
- TG Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit • GlobeNewswire Inc. • 11/10/2025 09:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/07/2025 10:01:49 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/05/2025 09:31:23 PM
